Clinical Trials

19 enrolled

Dermatologic

Melanoma

NCT06188741 2026-03-12

NF114

Phase 2 Recruiting

200 enrolled

Phase 1 Not yet recruiting

Neurofibromatosis 1, Neurofibroma, Plexiform

NCT06502171 2026-03-12

NF113

30 enrolled

Neurofibromatosis 1, Neurofibroma, Plexiform

NCT02407405 2026-03-05

MEK 1/2 Inhibitor Selumetinib (AZD6244 Hydrogen Sulfate) in Adults With Neurofibromatosis Type 1 (NF1) and Inoperable Plexiform Neurofibromas

36 enrolled

Phase 1/2 Active not recruiting

Neurofibromatosis 1, Neurofibroma, Plexiform

NCT01362803 2026-03-02

AZD6244 Hydrogen Sulfate for Children With Nervous System Tumors

99 enrolled 3 FDA

Neurofibromatosis 1, Pain, Neurofibroma, Plexiform

NCT03801369 2026-02-25

AMTEC IIT: Phase 2 Multiarm Study in TNBC

Phase 2 Terminated

24 enrolled 16 charts

Breast

Triple Negative Breast Neoplasms

NCT05101148 2026-02-23

Phase I Study to Assess the Effect of Food on the PK and Gastrointestinal Tolerability of Selumetinib in Adolescent Children With Neurofibromatosis Type 1 Related Plexiform Neurofibromas

24 enrolled

Neurofibromatosis 1

NCT05253131 2026-02-11

Trial of Selumetinib and Bromodomain Inhibitor With Durvalumab for Sarcomas

41 enrolled

CNSSarcoma

Neurofibromatosis 1, Sarcoma, Neurofibrosarcoma

NCT02143466 2026-01-30

AZD9291 in Combination With Ascending Doses of Novel Therapeutics

344 enrolled

Advanced Non Small Cell Lung Cancer

NCT04590235 2026-01-30

A Study of Selumetinib in Chinese Paediatric and Adult Subjects With Neurofibromatosis Type 1 (NF1) and Inoperable Plexiform Neurofibromas (PN)

32 enrolled

Neurofibromatosis 1, Neurofibroma, Plexiform

NCT03392246 2026-01-22

A Phase 2 Study of Osimertinib in Combination With Selumetinib in EGFR Inhibitor naïve Advanced EGFR Mutant Lung Cancer

25 enrolled

Phase 3 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT02813135 2026-01-16

ESMART

Phase 1/2 Recruiting

472 enrolled

Tumor-Agnostic

Neoplasms

NCT04924608 2026-01-12

KOMET

145 enrolled 17 charts 1 FDA

Neurofibromatosis 1, Neurofibroma, Plexiform

NCT02546661 2025-12-29

BISCAY

MyeloidOther hematologic neoplasm

117 enrolled

Genitourinary

Muscle Invasive Bladder Cancer

NCT03326310 2025-12-29

Selumetinib and Azacitidine in High Risk Chronic Blood Cancers

Phase 1 Recruiting

18 enrolled

Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Primary Myelofibrosis

NCT05309668 2025-12-18

SPRINKLE

Phase 1/2 Active not recruiting

36 enrolled 37 charts

Neurofibromatosis 1

NCT02151084 2025-12-16

A Study of Different Dosing Schedules of Selumetinib With Cisplatin/Gemcitabine (CIS/GEM) Versus CIS/GEM Alone in Biliary Cancer

57 enrolled

Gallbladder Neoplasms, Recurrence

NCT00463814 2025-11-13

AZD6244 (ARRY-142886) Solid Oral Dosage Formulation in Participants With Advanced Solid Malignancies

58 enrolled

Tumor-Agnostic

Neoplasms

NCT00600496 2025-11-13

A Phase I, Open-Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD6244 (ARRY-142886)

BreastDermatologicGastrointestinalGenitourinaryThoracic

140 enrolled

Breast Neoplasms, Colonic Neoplasms, Kidney Neoplasms, Lung Neoplasms, Melanoma, Neoplasms

NCT03581487 2025-11-05

Durvalumab, Tremelimumab, and Selumetinib in Treating Participants With Recurrent or Stage IV Non-small Cell Lung Cancer

Phase 1/2 Completed

40 enrolled

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT03162627 2025-10-14

Selumetinib and Olaparib in Solid Tumors

Phase 1/2 Not yet recruiting

90 enrolled

Breast

Breast Neoplasms

NCT06735820 2025-07-03

MEKMDM2

45 enrolled

CNSSarcoma

Neurofibromatosis 1, Neurofibrosarcoma

NCT02664935 2025-05-21

National Lung Matrix Trial: Multi-drug Phase II Trial in Non-Small Cell Lung Cancer

423 enrolled

Adenocarcinoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell, Lung Neoplasms

NCT03095248 2025-04-22

SEL-TH-1601

Phase 2 Terminated

10 enrolled 9 charts

Ependymoma, Glioma, Meningioma, Neuroma, Acoustic, Neurofibromatosis 2

NCT02188264 2025-02-11

Selumetinib and Cyclosporine in Treating Patients With Advanced Solid Tumors or Advanced or Metastatic Colorectal Cancer

40 enrolled

Colorectal Neoplasms

NCT03213691 2025-02-05

Selumetinib Sulfate in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial)

21 enrolled 11 charts

CNSLymphoid

Lymphoma, Non-Hodgkin, Neuroblastoma, Central Nervous System Neoplasms

NCT03944772 2025-01-30

ORCHARD

247 enrolled

Carcinoma, Non-Small-Cell Lung

NCT02299999 2025-01-15

SAFIR02_Breast

1,460 enrolled

Breast

Breast Neoplasms

NCT06763315 2025-01-08

LS-NF1PNs

50 enrolled

Neurofibromatosis 1, Neurofibroma, Plexiform

NCT03833427 2024-11-07

MK-5618-001

Phase 1 Terminated

32 enrolled 17 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body

NCT01306045 2024-10-01

Molecular Profiling and Targeted Therapy for Advanced Non-Small Cell Lung Cancer, Small Cell Lung Cancer, and Thymic Malignancies

647 enrolled 17 charts

Carcinoma, Non-Small-Cell Lung, Thymoma, Small Cell Lung Carcinoma

NCT06620354 2024-10-01

Clinical Study on the Treatment of Type I Neurofibromatosis With Smeitinib Hydrosulfate Capsule

33 enrolled

Neurofibromatosis 1

NCT06621082 2024-10-01

The Clinical Study of the Treatment of Patients With Type I Neurofibromatosis With Smetinib Hydrosulfate Capsule

19 enrolled

Neurofibromatosis 1

NCT01256359 2024-08-15

DOC-MEK

83 enrolled 60 charts

Dermatologic

Melanoma

NCT02393690 2024-07-26

Iodine I-131 With or Without Selumetinib in Treating Patients With Recurrent or Metastatic Thyroid Cancer

60 enrolled 12 charts

EndocrineHead & Neck

Thyroid Cancer, Papillary, Thyroid Neoplasms, Adenocarcinoma, Follicular

NCT02337530 2024-03-21

Selumetinib in Patients Receiving Pemetrexed and Platinum-based Chemotherapy in Advanced or Metastatic KRAS Wildtype or Unknown Non-Squamous NSCLC

62 enrolled 13 charts

Carcinoma, Non-Small-Cell Lung

NCT02117167 2024-01-10

SAFIR02_Lung

999 enrolled

Non-small Cell Lung Cancer Metastatic

NCT03433183 2023-12-26

SARC031: MEK Inhibitor Selumetinib (AZD6244) in Combination With the mTOR Inhibitor Sirolimus for Patients With Malignant Peripheral Nerve Sheath Tumors

21 enrolled

CNSSarcoma

Neurofibromatosis 1, Neurofibrosarcoma

NCT02768766 2023-08-31

Intermittent Selumetinib for Uveal Melanoma

42 enrolled

Dermatologic

Uveal Melanoma, Melanoma

NCT05825365 2023-08-14

PROTECT

Phase 2 Withdrawn

Neurofibromatosis 1, Neurofibroma, Plexiform

NCT01783197 2023-08-04

Study of Selumetinib in Patients With Previously Treated or Untreated Advanced/Metastatic NSCLC

39 enrolled

Carcinoma, Non-Small-Cell Lung

NCT03745989 2023-07-27

MK-8353-014

LymphoidOther hematologic neoplasm

30 enrolled 19 charts

Tumor-Agnostic

Neoplasm Metastasis

NCT03705507 2023-05-11

SeluDex

Phase 1/2 Terminated

12 enrolled

Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT01160926 2023-04-24

DREAMtherapy

Phase 1 Terminated

31 enrolled

Rectal Neoplasms

NCT02503358 2023-03-21

Selumetinib and Paclitaxel as Second-Line Treatment in Treating Patients With Stage IIIB-IV Non-small Cell Lung Cancer

23 enrolled

Carcinoma, Non-Small-Cell Lung

NCT01146756 2023-02-15

MEKRT

21 enrolled

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT01248247 2022-01-12

BATTLE-2 Program: A Biomarker-Integrated Targeted Therapy Study in Previously Treated Patients With Advanced Non-Small Cell Lung Cancer

334 enrolled 14 charts

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT01134601 2021-12-01

A Phase I Study of AZD6244 in Combination With Capecitabine and Radiotherapy in Locally Advanced Adenocarcinoma of the Rectum

Phase 1 Terminated

1 enrolled 7 charts

Rectal Neoplasms

NCT01586624 2021-10-07

A Phase I Trial of Vandetanib (AZD6474) and Selumetinib (AZD6244) for Solid Tumours Including Non Small Cell Lung Cancer (VanSel-1)

61 enrolled 23 charts